Vasa Therapeutics Reports the Initiation of the P-I Trial Evaluating VS-041 for the Treatment of HFpEF
Shots:
- The company received the MHRA’s approval to initiate a FIH P-I HV trial of VS-041 (oral) for the potential treatment of heart failure with preserved ejection fraction (HFpEF)
- This P-I study will evaluate the safety, tolerability & PK of VS-041 in healthy volunteers, alongside Vasa also received a $11M seed funding led by Orphinic Scientific, i&i Biotech Fund among others
- Preclinical study co-funded by the ERDF & Polish NCRD showed, VS-041 significantly reduced cardiac fibrosis and improved diastolic heart function, preventing the release of endotrophin from primary human cardiac fibroblasts. During GLP toxicology assessments, it exhibited significant safety & tolerability.
Ref: Vasa Therapeutics | Image: Vasa Therapeutics
Related news:- Novo Nordisk Reports P-III Trial (STEP-HFpEF) Results of Semaglutide for Heart Failure with Preserved Ejection Fraction and Obesity
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
